Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effectiveness of Levomilnacipran in Healthy Males
NCT03249311Phase 4Unknown
- Sponsor
- University of Ottawa
- Start
- Mar 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of levomilnacipran in major depressive disorder (MDD) (3 arms), sponsored by University of Ottawa. Primary endpoints: Norepinephrine reuptake inhibition capacity at 24 months and Serotonin reuptake inhibition capacity at 24 months. Status: unknown.
02
Drugs
levomilnacipran
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03249311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03249311.